Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
14h
Pharmaceutical Technology on MSNAstraZeneca director says AI must be a “thought partner” in drug discoveryAstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.
15h
Pharmaceutical Technology on MSNBoehringer Ingelheim and Salipro enter drug discovery partnershipThe partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.
The coffee-machine-sized printer produces 3D humanlike tissue that should allow for better testing and development of ...
22h
Pharmaceutical Technology on MSNInsilico raises $110m to develop drug pipeline and AI platformInsilico Medicine has completed a Series E round, raising $110m to progress the development of its pipeline of drugs and AI ...
For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...
The company granted stock options to purchase an aggregate of 157,150 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 107,500 shares of Nurix common ...
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results